HIVE vs HUT

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 12, 2026

HIVE

65.2
AI Score
VS
HIVE Wins

HUT

59.1
AI Score

Investment Advisor Scores

HIVE

65score
Recommendation
HOLD

HUT

59score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric HIVE HUT Winner
Forward P/E 62.8931 138.8889 HIVE
PEG Ratio 0 0 Tie
Revenue Growth 73.5% -14.9% HIVE
Earnings Growth -99.9% 125.7% HUT
Tradestie Score 65.2/100 59.1/100 HIVE
Profit Margin -98.5% -169.8% HIVE
Beta 1.00 1.00 Tie
AI Recommendation HOLD HOLD Tie

Relative Price Performance (Last 90 Days)

HIVE 1M: -28.6% · 3M: -40.5% HUT 1M: -21.7% · 3M: -31.4%

Current Technical Phase

HIVE

Markdown
Sell / avoid

Price below a falling SMA50 (slope -13.0%), weak momentum, RSI 32

RSI (14): 31.9 · Price: $1.60

HUT

Markdown
Sell / avoid

Price below a falling SMA50 (slope -10.4%), weak momentum, RSI 44

RSI (14): 43.5 · Price: $58.61

Fundamentals Snapshot

Metric HIVE HUT
Market Cap — —
Forward P/E -3.4 -10.9
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth 0.7% -0.1%
Gross Margin 0.4% 0.6%
Operating Margin -0.6% 4.4%
EPS -1.53 -4.69
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, HIVE is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.